Does Zosyn cover Listeria

Antibiotics in the ICU are in some ways simpler than antibiotic therapy for less ill patients.  IV access isn't an issue.  Patients are critically ill, so we're justified in using broad-spectrum agents initially.  There is considerable variation in this between different hospitals, so when in doubt consider your local antibiogram and consult with pharmacists and infectious disease specialists.

when to start antibiotics? 

• Antibiotics shouldn't be started blindly (without a defined source of infection) unless the patient has septic shock or neutropenic fever.
• A positive culture may represent infection or colonization (bacteria present without causing disease).  Colonization commonly occurs in the bladder of anuric or catheterized patients, or sputum of intubated patients.  Don't treat colonization except in very specific situations (e.g. urinary colonization in pregnancy).
• If possible, get cultures before starting antibiotics.

choosing drug & dose

• Septic patients may have increased drug clearance, so antibiotics should generally be dosed on the higher end of dose ranges.
• Review which antibiotics patient has been exposed to recently; try to avoid these if possible.
• Review recent culture data.  Try to choose antibiotics that cover pathogens that the patient has grown in the recent past.

narrowing & discontinuing ASAP

• Keep track in your notes of how long the patient has been on each antibiotic.  Have some sort of plan regarding when to discontinue antibiotics and follow it.
• Use of procalcitonin has been shown to limit antibiotic exposure, while possibly improving patient outcomes.

treatment failure

• If a patient is failing antibiotic therapy, broadening coverage is usually not the answer.
• Common causes of treatment failure include:
  • Wrong initial diagnosis
  • Under-dosing
  • Development of a new hospital-related problem (e.g. volume overload, superinfection at different site, drug fever)
  • Requirement for surgical/percutaneous drainage

metabolism & clearance

• Antibiotics may be metabolized in the liver (often into inactive metabolites) or they may be excreted unchanged in the urine or bile.
• Hepatic metabolism/excretion is generally convenient, because this means the drug dose doesn't need to be adjusted based on renal function.
• Excretion of unchanged drug in the urine is ideal for treatment of urinary tract infections, because this will often produce very high drug concentrations in the kidney and bladder.  Likewise, excretion of unchanged drug in the bile is ideal for biliary or intestinal infections.
  • Urinary drug concentrations depend on serum level, percent excreted in the urine, and how concentrated the urine is.

bactericidal vs. bacteriostatic

• An antibiotic which is bactericidal kills bacteria, whereas an antibiotic which is bacteriostatic stops bacteria from dividing.
• Traditionally it was believed that cidality was desirable for severe infections.  However, cidality may actually be dangerous if this leads to rapid lysis of bacteria leading to a huge release of bacterial products (e.g. endotoxin) causing uncontrolled inflammation.
  • For example:  Antibiotics which inhibit protein synthesis (e.g. clindamycin and linezolid) cause immediate cessation of toxin secretion in patients with toxic shock.  They are used specifically for this reason – to shut down toxin synthesis (rather than necessarily immediately destroying all the bacteria).
• The concept that bactericidal antibiotics are superior is based on a petri-dish model of infectious disease, wherein the antibiotic is relied upon to kill the bacteria.  However, this model isn't very accurate – in vivo, the antibiotic is just assisting the patient's immune system in containing the infection.
  • Severe neutropenia is one situation where the petri-dish model may actually be accurate, so cidal antibiotics might be desirable in that context.
• Overall, the focus on cidality is probably misplaced.  In some situations this may be important, but other factors may be equally if not more important (e.g. tissue penetration, pharmacokinetics).  Just because an antibiotic is bacteriostatic doesn't mean that it's not extremely effective.
  • A recent analysis of over fifty RCTs found no benefit of cidal antibiotics compared to static antibiotics, so the clinical superiority of cidal antibiotics may be mostly mythological.(29293890)

percent protein binding

• Protein binding refers to the percent of drug in the blood which is bound to albumin.  Only unbound drug is active against bacteria.
• A high percent protein binding (>90%) may have the following consequences:
  • Creates a reservoir of drug which is bound to albumin (which may extend the drug's half-life).
  • Reduces renal clearance (only free drug is cleared).
  • Reduces tissue penetration (only free drug is able to leave the bloodstream and penetrate tissues).
• Depending on the clinical context, a high percent protein binding could be helpful (e.g. long half-life extends dosing interval) or harmful (e.g. impaired tissue penetration).

volume of distribution (Vd)

• This is the effective volume into which the drug is diluted following administration.  There are roughly three patterns of drug distribution:
• (1) Drugs that stay in the extracellular fluid
  • The extracellular fluid has a volume of ~0.3 L/kg, so drugs that stay in the extracellular fluid will have a Vd of roughly 0.1-0.3 L/kg
  • Drugs with this pharmacology may work well for extracellular infections (e.g. bacteremia).
• (2) Drugs that distribute throughout the total body water (intracellular and extracellular fluid).
  • The extracellular and intracellular fluids have a volume of ~0.7 L/kg, so drugs that distribute evenly through this volume will have a Vd close to this value.
  • Many drugs in this group have excellent tissue penetration (with the possible exception of vancomycin).
• (3) Drugs that leave the blood.
  • Some drugs are absorbed avidly by the tissues, with a tendency to concentrate within tissues.  This may be seen with lipophilic drugs which rapidly leave the blood and may form a depot in fat tissues.  These drugs will have a Vd which is substantially greater than total body water (Vd >> 0.7 L/kg).
  • These drugs may have excellent tissue penetration, but may not be optimal for bloodstream infections.

meningeal penetration

• The pharmacokinetics of treating meningitis depends primarily on three factors:
  • 1) Serum drug level.
  • 2) What percent of the serum drug enters the meninges (greater if smaller molecular weight, more lipophilic, and less protein binding).
  • 3) How high a level is required to inhibit bacterial growth (minimum inhibitory concentration; MIC)
• The table below shows the fraction of serum levels achieved in the meninges for different antibiotics.  This is useful, but it's only one piece of the puzzle (#2 above).  It's not intended to dictate which antibiotics may be used to treat meningitis, but rather to provide a general concept of relative CNS penetration.
• For patients without CNS infection, having a low entry into the CNS may be desirable to avoid neurologic adverse events (the blood-brain barrier was designed for a reason!).

oral bioavailability

• Oral bioavailability isn't generally a major consideration in the ICU.  However, this may become relevant in some situations (e.g., limited IV access, volume overload).
• Agents with very high bioavailability (>~90%) include the following:
  • Clindamycin (but oral administration may increase risk of C. difficile).📖
  • Metronidazole.📖
  • Trimethoprim-sulfamethoxazole.📖
  • Doxycycline.📖
  • Linezolid.📖
  • Rifampin.📖
  • Cephalexin.
  • Nitrofurantoin.📖
  • Fluoroquinolones.📖

Antibiograms vary greatly in different geographic locales.  The following antibiogram is intended only as a rough concept; whenever possible, it's preferable to use local data.

First-line agents for common gram-positive pathogens (28961942)

• MSSA – Cefazolin or nafcillin.  Nafcillin required for CNS penetration.
• MRSA – Vancomycin, linezolid (not preferred for bacteremia), or daptomycin (ineffective in pneumonia)
• Staphylococcus lugdunensis (“slug”) – Vancomycin empirically, narrow to oxacillin if sensitive.
• Enterococcus faecalis – Ampicillin preferred (99% sensitive), may be superior to vancomycin.
• Enterococcus faecium (VRE) – Linezolid is first-line, daptomycin 2nd line.
• Enterococcus faecium (non-VRE) – Vancomycin or linezolid
• Streptococcus anginosus – Penicillin G is 1st line, ceftriaxone is 2nd line
• Streptococcus pyogenes (Group A strep) or Streptococcus agalactiae (Group B strep) – Penicillin G is 1st line, cefazolin is 2nd line
• Streptococcus pneumoniae (not meningitis) – Ceftriaxone is 1st line, Vancomycin is 2nd line in severe allergy.
• Listeria spp. – Ampicillin is 1st line, trimethoprim/sulfamethoxazole is 2nd line.

Treatment of gram-negative pathogens (before sensitivity data is available)

• E. coli, Klebsiella pneumoniae, Klebsiella oxytoca.
  • No risk factors for ESBL species:  Ceftriaxone or cefepime.
  • Risk factors for ESBL species:  Carbapenem.
• Proteus species:  Piperacillin-tazobactam or cefepime.
• Enterobacter or Citrobacter:  Cefepime or carbapenem.
• Pseudomonas:  Piperacillin-tazobactam, cefepime, or meropenem.

aminoglycoside dosing

• Gentamicin synergy for endocarditis:
  • Traditional dosing:  1 mg/kg q8hr (target 1-hr peak of 3 ug/ml, and trough <1 ug/ml).(26373316, 26320109)
  • Once-daily dosing (3 mg/kg daily) may be safer, albeit possibly less effective (advocated in European endocarditis guidelines).(26320109)
• General dosing strategy shown below.
  • In morbid obesity, consider using an adjusted body weight (Adjusted Body Wt = 0.6(ideal body wt)+0.4(actual body wt)).

pharmacology

• Administered only IV/IM.
• Excreted unchanged in the urine.
• Half-life is normally ~2.5 hours.
• Plasma protein binding is low (~5-10%).
• Volume of distribution (Vd) is ~0.25 L/kg.
• Penetration:
  • Lung penetration is borderline (bronchial secretion level is 2/3rds serum level, and drug may not function well in acidic environment within consolidated lung tissue).
  • Poor penetration of many tissues (brain, bile, prostate, meninges).
  • Excellent renal penetration.

agents

• Gentamicin:  Best gram-positive coverage.
• Tobramycin:  Workhorse aminoglycoside, good gram-negative coverage.
• Amikacin:  Best gram-negative coverage (often reserved for resistant pseudomonas).

spectrum

• Gram-positives:
  • Covers MSSA and Enterococcus faecalis.
  • Misses Staph. saprophyticus.
• Gram-negatives:
  • Excellent coverage of Enterobacteriaceae and Pseudomonas.

use

• Gentamicin is used for synergy against Enterococcus faecalis endocarditis, with other agents (at reduced dose of 1 mg/kg q8hr).
• Gram negative bacteremia with refractory shock.
• Urinary tract infection.

toxicity/contraindications

• Nephrotoxicity, ototoxicity.
• Neuromuscular blockade (may be an issue in severe hypocalcemia or myasthenia gravis).

Medscape monographs:  Gentamycin; Tobramycin; Amikacin

ampicillin dosing

• Ampicillin
  • 1-2 grams IV q4-6
    • Meningitis/endocarditis:  2 grams IV q4.(26373316, 26320109)
  • GFR 30-50 ml/min:  extend dosing interval to q8.
  • GFR 10-30 ml/min:  extend dosing interval to q8-q12.
  • GFR <10 ml/min:  extend dosing interval to q12-q16.
• Ampicillin-Sulbactam
  • 1.5-3 grams q6hrs (usually 3 grams q6hr).
    • Endocarditis:  3 grams IV q6.(26373316, 26320109)
  • GFR 30-50 ml/min:  extend dosing to q6-q8.
  • GFR 10-30 ml/min:  extend dosing to q12.
  • GFR < 10:  extend dosing to q24.

pharmacology

• Excretion:  90% excreted in urine unchanged.
• Protein binding:  25%
• Vd:  0.25 L/kg
• Penetration:  Widely distributed (e.g. urine, pleural fluid, lung), including inflamed meninges.

spectrum

• Ampicillin
  • Gram-positives:  Enterococcus (~80% of E. faecalis, but only rarely covers E faecium); most Streptococci, most Streptococcus pneumoniae.  Misses Staphylococcus saprophyticus.(31608743)
  • Gram-negatives:  Some E. Coli, Proteus mirabilis.
  • Anaerobes:  Covers many, including clostridium (but not C. difficile).
  • Listeria monocytogenes.
• Ampicillin-Sulbactam
  • Gram-positives:  Enterococcus (improved coverage of E. faecium compared to ampicillin); most streptococci, most Streptococcus pneumoniae, MSSA, Staph. saprophyticus.
  • Haemophilus influenzae, Moraxella catarrhalis.
  • Gram-negatives:  Better than ampicillin but still mediocre coverage, with increasing resistance (overall inferior to ceftriaxone).  Best coverage for Klebsiella pneumoniae and Proteus mirabilis.
  • Good anaerobic coverage.

use

• Ampicillin may be drug of choice for:
  • Enterococcus faecalis.
  • Listeria monocytogenes.
  • Sensitive strains of E. Coli, Proteus mirabilis.
• Ampicillin-Sulbactam
  • Community-acquired empyema (may easily transition to oral amoxicillin-clavulanic acid).
  • Epiglottitis (covers Haemophilus influenzae).
  • Diabetic foot infection, mild.

toxicity/contraindications

• Ampicillin
  • Skin rash (more common with mononucleosis, CLL, or allopurinol use)
  • Cytopenias (Coombs-positive hemolytic anemia, neutropenia, thrombocytopenia)
  • Acute interstitial nephritis, hepatitis, drug fever
  • Seizure, myoclonus (especially high doses in renal failure)
•  Ampicillin-Sulbactam
  • Similar to ampicillin, increased risk of cholestatic hepatitis

Medscape monographs:  Ampicillin; Ampicillin-Sulbactam

aztreonam dosing

• GFR >30 ml/min:  1-2 grams IV q8hr (Meningitis or morbid obesity: consider 2 grams q6hr).
• GFR < 10-30 ml/min: 1-2 grams q12hr.
• GFR < 10 ml/min:  1-2 grams q24hr.
• CRRT 1 gram q12.

pharmacology

• Excreted unchanged in urine:  65%.
• Plasma protein binding:  56%.
• Volume of distribution:  0.2 L/kg.
• Tissue penetration:  widely distributed throughout body, including CNS.  High levels in bile and urine.

spectrum

• Covers gram-negatives well (including pseudomonas), but nothing else.
• May fail in species that have inducible AmpC beta-lactamases (e.g., Serratia spp., Providencia spp., Proteus vulgaris, Citrobacter spp., Enterobacter spp.).

use

• Excellent gram-negative coverage, safe for use in patient with anaphylaxis to penicillin (but might cross-react with ceftazidime).(25124380)
• Can be used for many gram-negative infections (e.g. pneumonia, soft tissue, urinary tract, bacteremia).
• Reasonable choice for patient found to have gram-negative bacteremia.

toxicity/contraindications

• Contraindication:  Ceftazidime allergy (may be cross-allergic).(25124380)  However, overall seems to have low tendency to cause allergic reaction or side-effects.
• Abnormal liver function tests.
• Thrombocytopenia, neutropenia.
• Seizure.

Medscape monograph:  Aztreonam

carbapenem dosing

• Meropenem:
  • GFR >50:  1-2 grams q8 (higher end for pseudomonas, meningitis, or morbid obesity).(23147743)
  • GFR 30-50:  1-2 grams q12.
  • GFR 10-30:  500-1,000 mg  q12.
  • GFR <10:  500-1,000 mg q24.
• Ertapenem:
  • GFR >30 ml/min:  1 gram IV q24hr (may consider higher dose in morbid obesity or severe illness).
  • GFR <30 ml/min:  500 mg IV q24hr.

carbapenem pharmacology

• Meropenem:
  • Excreted unchanged in the urine (70%).
  • Protein binding 2% (promoting wide distribution into tissues).
  • Volume of distribution 0.35 L/kg.
  • Penetration:  well distributed into most tissues including CNS.
• Ertapenem:
  • Excreted unchanged in urine (40%).
  • Protein binding of 95% – this creates a reservoir of drug in the blood, extending the half-life and allowing ertapenem to be given once daily.
  • Volume of distribution 0.12 L/kg.
  • Penetration:  Higher protein-binding reduces its penetration compared to meropenem (e.g., giving ertapenem poor penetration of bile, peritoneal fluid, and prostate).

spectrum: meropenem

• Gram-positives:
  • Generally very good (including MSSA, Enterococcus faecalis, Staph. saprophyticus).
  • Misses MRSA and Enterococcus faecium.
• Gram-negative coverage:
  • Overall excellent (including Pseudomonas, ESBL and AmpC multidrug resistant species).
  • Some carbapenem resistance is starting to emerge among enterobacteriaceae (especially among Klebsiella pneumoniae); this varies widely depending on geography.
• Anaerobic coverage:  Excellent (but doesn't cover C. difficile).

spectrum:  ertapenem

• Main differences compared to meropenem:
  • 1) Lacks coverage of pseudomonas and acinetobacter.
  • 2) Limited activity against enterococci.
• May be superior for non-pseudomonas gram-negatives (due to broad use of meropenem and development of meropenem resistance).

use

• Broad-spectrum beta-lactam antibiotics with a range of potential applications, particularly for nosocomial infections (e.g., pneumonia, intra-abdominal infections, urinary tract infections, bacteremia, soft tissue infections).  Unlike most beta-lactams, carbapenems decrease lipopolysaccharide release from gram-negative bacteria, which could give them a theoretical advantage in the treatment of gram-negative septic shock.
• Front-line choice for multi-drug resistant gram-negative bacteria (e.g. bacteria with inducible AmpC beta-lactamases 📖, ESBL bacteria 📖).
• Patient with history of anaphylaxis following penicillin exposure who requires broad-spectrum coverage.  Carbapenems (especially meropenem) have an extremely low risk of allergic reaction.📖  Using a carbapenem may be safer than a multi-drug regimen (e.g. vancomycin/aztreonam/metronidazole) and faster to administer in septic shock.  Meropenem can actually be given as a bolus.
• Meropenem has better tissue penetration (e.g., allowing it to be used in meningitis), whereas ertapenem has a longer half-life (allowing once-daily dosing).

toxicity/contraindications

•  Meropenem:
  • Seizure.
  • Thrombocytopenia.
  • Drug fever.
•  Ertapenem:
  • DRESS syndrome.
  • Seizures, delirium, myoclonus/tremor.

Medscape monographs:  Ertapenem; Meropenem

cefazolin dosing

• GFR >50 ml/min:  1-2 grams IV q8.
  • Endocarditis or bacteremia:  2 grams IV q8.(26373316, 26320109)
  • Morbid obesity:  consider 2 grams IV q6.
• GFR 30-50 ml/min:  1-2 grams IV q12.
• GFR 10-30 ml/min:  0.5-1 gram IV q12.
• GFR <10 ml/min:  0.5-1 gram IV q24.

pharmacology

• Excreted unchanged by kidneys (90%)
• Protein binding:  80%
• Vd:  0.2 L/kg
• Penetration:  Good penetration of lungs, joints, bone, prostate, and bile.  However, poor CNS penetration is a major limitation of cefazolin.

spectrum

• Gram-positives:
  • All non-enterococcal streptococci (e.g. streptococcus groups A, B, C, G).
  • MSSA, Staph. saprophyticus, coagulase-negative staph which are sensitive to oxacillin.
• Gram-negatives
  • Usually effective for E. coli, Klebsiella pneumoniae, and Proteus mirabilis.
  • Not generally adequate for empiric therapy against gram-negative infections, but may be used as step-down therapy once sensitivities available.

use

• Empiric coverage before culture known:
  • Cellulitis (treatment of choice for non-purulent cellulitis).
  • Endocarditis (in combination with vancomycin).
• After culture & sensitivity are known:
  • Bacteremia and/or endocarditis.
  • Pneumonia (e.g., due to MSSA or Group A streptococcus).
  • Urinary tract infection (e.g., due to sensitive E. coli or Proteus mirabilis).
• Cefazolin vs. nafcillin for MSSA 🤜🥊
  • Cefazolin is better tolerated, with lower rates of kidney injury.
  • Theoretically, cefazolin may fail due to an “inoculum effect” wherein a large burden of staph produces enough staphylococcal penicillinase to inactivate cefazolin.(29977970, 32757525)  However, overall there seems to be a growing body of evidence that cefazolin has superior clinical efficacy compared to nafcillin.(30476572, 30928559).  Thus, the optimal antibiotic choice remains debatable.
  • Nafcillin has superior CNS penetration, so nafcillin is required in patients with CNS involvement.

toxicity/contraindications

• PCN allergy is not a contraindication.  Cefazolin has a unique side-chain, which isn't cross-allergic with any other beta-lactam.(24637693)  It can also be used in patients with hypersensitivity reactions to nafcillin.(24637693)
• Drug rash, drug fever
• Transaminitis
• Neutropenia, thrombocytopenia
• Seizures, delirium

Medscape monograph:  Cefazolin

ceftriaxone dosing

• 1 gram q24:  Typical dose for most infections.
• 2 grams q24:
  • Severe infection (e.g., endocarditis).(26373316, 26320109)
  • Obesity.
• 2 grams q12:
  • Meningitis or other CNS infection.
  • Endocarditis with cephalosporin-resistant pneumococcus or enterococcus.(26373316, 26320109)
• No renal adjustment.

pharmacology

• Roughly 50% excreted unchanged by kidneys, remainder excreted unchanged by liver.  In renal failure, the liver picks up the slack so no dose adjustment needed.  Achieves high levels in both urine and bile.
• Protein binding of 90% promotes an unusually long half-life of ~7 hours (longer than most beta-lactams).
• Volume of distribution 0.2 L/kg
• Good tissue penetration, including CNS (although higher doses needed to penetrate meninges).

spectrum:  ceftriaxone covers: 

• Gram-positives
  • MSSA:  Does seem to cover, but inferior to cefazolin and suboptimal for MSSA bacteremia.(28942574)  Reduced activity against Staph. saprophyticus.(31608743)
  • All non-enterococcal streptococci (misses enterococcus).
  • Streptococcus pneumoniae (resistant strains will usually still be cured clinically, with the exception of meningitis).
• Haemophilus influenzae, Moraxella catarrhalis.
• Neisseria meningitidis.
•  Gram-negatives:
  • Generally good coverage (including E. coli, Klebsiella pneumoniae, Proteus mirabilis).
  • Misses:  Pseudomonas, ESBL organisms.
  • Should be avoided in species that may have inducible AmpC beta-lactamases (e.g., Serratia spp., Providencia spp., Proteus vulgaris, Citrobacter spp., Enterobacter spp.).

use

• Pneumonia.
• Meningitis (covers nearly everything; will miss listeria and resistant streptococcus pneumoniae).
• Urinary tract infection without septic shock.
• Bacteremia, endocarditis.
• Peritonitis, prophylaxis in cirrhotic patients with GI hemorrhage.

toxicity/contraindications

• Cholecystitis (may crystallize in gallbladder causing pseudo-biliary lithiasis).
• Hepatitis.
• Neutropenia, thrombocytopenia.
• Drug rash, anaphylaxis.
• Delirium.

Medscape monograph:  Ceftriaxone

ceftazidime dosing

• GFR >50 ml/min:  1-2 grams IV q8hr (2 grams for severe infection, meningitis, or morbid obesity).(22249886)
• GFR 30-50 ml/min:  1-2 grams IV q12hr.
• GFR 10-30 ml/min:  0.5-1 grams IV q12.
• GFR <10 ml/min:  0.5-1 gram IV q24.

pharmacology

• Widely distributed with good penetration, including CNS.
• Superior urinary concentration compared to ceftriaxone.

spectrum:  

• Gram-positive coverage is poor:
  • Ceftazidime loses activity against MSSA and penicillin-intermediate strains of Streptococcus pneumoniae.
  • Lacks activity against Staph. saprophyticus.(31608743)
• Haemophilus influenzae, Moraxella catarrhalis.
• Gram-negatives:
  • Good coverage of gram-negatives, including Enterobacteriaceae and Pseudomonas.
  • Should be avoided in species that may have inducible AmpC beta-lactamases.📖

ceftazidime is almost never the best antibiotic choice

• Cefepime is usually a better choice
  • a) Cefepime has better activity against gram-negatives, including species with inducible AmpC beta-lactamases.📖
  • b) Cefepime has greatly superior activity against gram-positives, so it's preferable for empiric therapy in septic shock (even in patients on vancomycin, as the vancomycin level is often subtherapeutic)
  • c) The safety profile of cefepime and ceftazidime are similar.(17158033)
• For a mildly ill patient with definite gram-negative infection (e.g., gram-negative rods detected in urine or blood), aztreonam is a more logical choice.
• Ceftazidime seems to have a particularly strong tendency to select out for drug-resistant pathogens (e.g. MRSA, multi-drug resistant pseudomonas).  For this reason some hospitals have removed ceftazidime from the formulary entirely.🌊

toxicity/contraindications

• Transaminitis.
• Drug fever.
• Delirium, often with myoclonus.  Seizures. (12627936)
• Hemolytic anemia, neutropenia, thrombocytopenia.
• Interstitial nephritis.

Medscape monograph:  Ceftazidime

cefepime dosing

• GFR >50 ml/min:  2 grams q8-12 hours:
  • 2 grams q8hr for Pseudomonas, multidrug resistant gram negatives, febrile neutropenia, CNS infections, or morbid obesity.(22249886)
• GFR 30-50 ml/min:  2 grams Q12-24.
• GFR 11-29 ml/min:  1-2 grams Q24.
• GFR < 11 ml/min:  500-1000 mg Q24.

pharmacology

• Excretion:  85% excreted unchanged in urine
• Protein binding:  20%
• Vd: 0.3 L/kg
• Penetration:  Good tissue penetration, including the CNS.  Positively charged R2 group gives the molecule a net even charge, improving penetration of gram-negative bacteria.

spectrum

• Gram-positives:
  • Covers MSSA, Staph. saprophyticus, most coagulase-negative staph, non-enterococcal streptococci, Streptococcus pneumoniae.
  • Lacks activity against enterococcus.
• Gram-negatives:
  • Covers Pseudomonas.
  • Excellent coverage of enterobacteriaceae (including species with AmpC inducible beta-lactamases 📖).
• Covers Haemophilus influenzae, Neisseria meningitidis.

uses include:  

• Community-acquired septic shock.
• Febrile neutropenia.
• Hospital-acquired infections (including pneumonia, bacteremia, intra-abdominal infections, CNS infections).
• Likely safe in patients with PCN anaphylaxis (virtually no reported cases of cefepime-induced anaphylaxis).(14763949)

toxicity/contraindications

• Drug fever.
• Neutropenia, thrombocytopenia, positive Coombs test which is sometimes accompanied by clinical hemolysis.
• CNS:  Seizure (including nonconvulsive status epilepticus); delirium (often with myoclonus).(12627936)
• Causes more C. difficile than piperacillin-tazobactam.(24140078, 14963072)

Medscape monograph:  Cefepime

ceftaroline dosing

• GFR > 50 ml/min:
  • Mild-moderate infections:  600 mg IV q12hr
  • Serious infections, endocarditis, staph bacteremia:  600 mg IV q8hr (28702467, 27520326)
• GFR 30-50 ml/min:  400 mg q12hr
• GFR 15-30 ml/min:  300 mg q12hr
• ESRD/HD:  200 mg q12hr
• Morbid obesity:  no dose adjustment

pharmacology

• Excretion:  64% excreted unchanged in urine
• Protein binding: 20%
• Vd: 20 L/kg
• Penetration:  Widely distributed, but only 10% CNS penetration

spectrum

• Gram-positives:  Covers MSSA, MRSA, coagulase-negative staph, Streptococcus pneumoniae, non-enterocccal streptococci, Enterococcus faecalis.
• Gram-negatives:  Generally good coverage, but misses pseudomonas and extended-spectrum beta-lactamase resistant organisms (ESBLs).

use

• Skin/soft tissue infection
• Pneumonia
• Endocarditis, bacteremia
  • Little evidence, but case series show ability to cure patients refractory to vancomycin or daptomycin.(28702467)
  • Combination of ceftaroline plus daptomycin may salvage highly refractory MRSA bacteremia.(28702467)
• Empiric antibiotic regimens designed to cover MRSA

toxicity/contraindications

• Nausea, diarrhea
• Rash
• Neutropenia (more problematic with longer courses)(28702467)
• Clostridioides difficile colitis
• Seizure

Medscape monograph:  Ceftraoline

clindamycin dosing

• 900 mg IV q8hr.
• Generally no dose adjustment for hepatic or renal dysfunction.
  • Consider reduction in combined kidney & hepatic dysfunction.

pharmacology

• High oral bioavailability (~90%); however, oral clindamycin may cause more Clostridioides difficile than IV clindamycin.
• Excretion:  Metabolized by liver, only 10% excreted unchanged in urine.
• Protein binding:  90%
• Vd: 1 L/kg (widely distributed).
• Penetration:
  • Good penetration of most tissues, except the CNS.
  • Actively transported into neutrophils and macrophages, causing concentration in abscesses.
  • Dissolves biofilms on hardware.
• Mechanism:  blocks protein synthesis by impeding release of protein from the 50S ribosome (same mechanism as macrolides).

spectrum

• Gram-positives:  Streptococcus pneumoniae, non-enterococcal streptococci, and staph (MSSA and some MRSA).
• Anaerobic coverage good, although increasing resistance among gut anaerobes (e.g. Bacterioides spp).
• Use caution if the bacteria is resistant to erythromycin, as some bacteria may be cross-resistant or have inducible resistance against clindamycin.  This may be evaluated using the D-test.

use

• Toxin suppression:
  • Severe Group A strep infections (e.g. toxic shock syndrome, necrotizing fasciitis).  The combination of clindamycin plus a beta-lactam is the gold standard therapy here.
  • Clostridium perfringens:  gas gangrene.
• Anaerobic coverage (however, metronidazole is generally superior for this).
  • Clindamycin can be useful for lung abscess, due to combined coverage of anaerobes and oral streptococcal spp.

toxicity/contraindications

• High tendency to induce Clostridioides difficile infection.
• Rashes, fever, anaphylaxis, erythema multiforme.
• May block neuromuscular transmission, contraindicated in myasthenia gravis.

Medscape monograph:  Clindamycin

daptomycin dosing

• 4-6 mg/kg IV daily:  Skin/soft tissue infections.
• 8-10 mg/kg IV daily:  Bacteremia.
• 10 mg/kg IV daily:  Staphylococcal endocarditis.(26373316, 26320109)
• 10-12 mg/kg IV daily:  Enterococcal endocarditis.(26373316, 26320109)
• For renal insufficiency (GFR <30), increase interval to q48.
• Morbid obesity:  use actual body weight.(17548489)
• When in doubt, dose high.  Higher-dose daptomycin may reduce the likelihood of treatment-emergent resistance, is generally well tolerated, and is not associated with excess toxicities (2015 IDSA endocarditis guidelines).(26373316)

pharmacology

• Excretion:  80% excreted unchanged in urine
• Protein binding:  92%
• Vd:  0.1 L/kg (small Vd corresponds to plasma and interstitial fluid)
• Penetration:  Distributes to bile and urine;  CSF penetration poor.
• Dosed once daily with post-antibiotic effect and half-life of ~8 hours.

spectrum

• Very broad spectrum against gram-positives (including MRSA and vancomycin-resistant enterococci).
• Emergence of daptomycin resistance may occur while treating Staph aureus (especially if previously treated with vancomycin or large burden of bacteria).

use

• MRSA endocarditis, bacteremia
  • Be careful about using daptomycin if vancomycin MIC is >2 (increased rates of resistance).
  • Resistance can emerge during therapy, which might be avoided somewhat by co-administration of a beta-lactam (daptomycin plus ceftaroline might be ideal).
• Skin/soft tissue infection.
• Urinary vancomycin-resistant enterococcus infection (daptomycin secreted in urine, might be 1st line here).
• Note:  Inactivated by surfactant in lung, so cannot be used for pulmonary infection.

toxicity/contraindications

• Rhabdomyolysis
  • Discontinuing statins might reduce risk.
  • Monitor creatinine kinase.  Discontinue daptomycin if creatinine kinase increases >2000 U/L, or >1000 U/L with symptoms of myopathy.
• False elevation of INR (lab artifact).  This may be sorted out by repeating INR before an infusion when daptomycin is at trough levels.
• LFT abnormality
• Acute eosinophilic pneumonia
• Peripheral neuropathy

Medscape monograph:  Daptomycin

doxycycline dosing

• Start with 200 mg loading dose in severe infection (otherwise steady-state drug levels won't be reached for a few days).(28819873)
• Usual dose:  100 mg q12 PO/IV (100% oral bioavailability)
• Meningeal dose:  200 mg q12.
• For moderate to severe legionella:  200 mg q12 hours for 72 hours, followed by 100 mg q12.(16669925)

pharmacology

• 100% oral bioavailability (however absorption impaired by aluminum, magnesium, calcium, iron, cholestyramine, or milk).
• Excretion:  30% excreted unchanged in the urine.  Mostly eliminated by the liver.
• Protein binding:  82%
• Vd: 0.75 L/kg
• Penetration:  Good penetration of most tissues (CSF reaches 25% serum level).
• Mechanism:  Inhibition of protein synthesis through 30s ribosomal binding blocking aminoacyl-tRNA (same as tigecycline).

spectrum

•  Gram-positives
  • Most streptococci
  • Streptococcus pneumoniae is increasingly resistant (~20% resistant).
  • Staph coverage is good (including coverage of ~80% of MRSA), but may fail to provide clinical cure en vivo.
• Gram-negatives
  • Some E. coli
  • Haemophilus influenzae, Moraxella catarrhalis
• Clostridia
• Atypicals:  Mycoplasma pneumoniae, Chlamydia pneumoniae, legionella
• Listeria monocytogenes
• Tick-borne illnesses (lyme, Rocky Mountain Spotted Fever, tularemia, ehrlichiosis, anaplasmosis).
• Zoonotic organisms (Coxiella burnetii, Yersinia pestis, Chlamydia psittaci, Bacillus anthracis, leptospirosis, Pasteurella multocida)

use

• Coverage for atypical organisms in patients with pneumonia, especially in the following situations:
  • 1) Patients who are at some risk for community-acquired MRSA pneumonia, but not enough risk to justify addition of linezolid or vancomycin (doxycycline has fair activity against community-acquired MRSA, but lacks evidence for efficacy in MRSA pneumonia).
  • 2) History of contact with animals.
• Coverage of almost all tick borne illnesses (e.g. anaplasmosis, Rocky Mountain Spotted Fever).   Unfortunately, doxycycline will miss babesiosis, so if your tick-exposed patient has hemolysis then babesiosis may require further investigation and specific treatment.
• Staph aureus skin and soft tissue infections.

toxicity/contraindications

• Generally well tolerated (appears to reduce the risk of Clostridioides difficile).(22563022, 18171186, 27025622, 28819873)
• GI irritant:  Nausea, vomiting if taken before/after meals; esophageal ulceration if taken orally without sufficient water.
• Vascular irritant:  Can cause phlebitis when given IV.
• Pancreatitis reported in a few case reports.(28912911)
• Stevens-Johnson syndrome.

Medscape monograph:  Doxycycline

Fluoroquinolones have little role in a modern ICU for the following reasons:

• 1) Increasing antibiotic resistance (e.g. >25% resistance of E. coli to ciprofloxacin in many locations).
• 2) Fluoroquinolones induce the emergence of multi-drug resistant bacteria to a much greater extent than most antibiotics.  Removal of fluoroquinolones from the ICU may help control pathogens such as C. difficile and MRSA.
• 3) Fluoroquinolones have traditionally been used for patients with penicillin allergy, but we are increasingly realizing that cephalosporins are fine for such patients.
• 4) Fluoroquinolones cause delirium, likely to a greater extent than most antibiotics.
• 5) Fluoroquinolones have recently been implicated in causing persistent neurologic abnormalities, which may be especially problematic among intubated patients (who are unable to report neurologic side-effects).  Fluoroquinolones can also cause connective tissue problems involving tendinopathy and possibly aortic aneurysm.  Consequently, the FDA has recommended avoidance of fluoroquinolones when possible in a black box warning.
• 6) Fluoroquinolones add very little to beta-lactam antibiotics when used for double-coverage of pseudomonas.
  • The concept of double-coverage of pseudomonas just isn't supported by evidence (more on this here).
  • If you are going to double-cover for pseudomonas, the only antibiotic that adds substantially to a beta-lactam is an aminoglycoside.  Adding a fluoroquinolone to an antipseudomonal beta-lactam is like adding a pistol to a cannon – it just doesn't add much (explained further here).

linezolid dosing

• 600 mg IV/PO q12hr (no adjustment for renal dysfunction; same dose provides meningeal coverage).
• Morbid obesity and severe infection, or co-administration with rifampin:  consider 600 mg IV/PO q8hr.

pharmacology

• 100% oral bioavailability.
• Excretion:  Mostly cleared by hepatic metabolism, but 30% is excreted unchanged in the urine.
• Protein binding:  31%
• Vd:  0.6 L/kg (approximately equal to total body water content)
• Penetration:  Outstanding tissue penetration, including lung and particularly CSF (may reach 70% serum levels).(22787406)

spectrum

• Broad coverage of gram-positives (including MRSA, vancomycin-resistant enterococci, streptococcal species, coagulase-negative staphylococci).
• Listeria

advantages of linezolid over vancomycin

1. Better tissue penetration of lung and brain.
2. No nephrotoxicity.
3. Linezolid suppresses toxin production (beneficial in toxic shock syndrome and community-acquired MRSA).
4. Superior spectrum of activity against enterococci (including coverage of vancomycin-resistant enterococci).
5. Vancomycin is cleared by the kidneys, which makes therapeutic levels hard to achieve in patients with augmented renal clearance.  In contrast, linezolid is cleared by the liver, making dosing and achievement of therapeutic levels easier.
6. MRSA is rapidly growing less sensitive to vancomycin (the phenomenon of “MIC creep”).  This is forcing us to target higher vancomycin levels, leading to greater vancomycin nephrotoxicity.  Over time this will become a more obvious problem (our evidentiary base of studies regarding linezolid vs. vancomycin lags 10-15 years behind current microbiologic trends).

use

• Pneumonia:  Arguably front-line agent for MRSA pneumonia.(22247123, 25355172, 25066668, 27208687, 24238896, 26382940, 24916853, 24420846, 23568605, 21163725, 18719064)  Will also work for other gram-positive pneumonia (e.g. MSSA, Streptococcus pneumoniae).
• Bacteremia:  In 2007, the FDA released a warning regarding the use of linezolid for catheter-related bloodstream infections (below).(17899228, 19072714)  This seems to represent a statistical fluke, especially because subsequent studies have shown that linezolid is effective for bacteremia.(25495779, 19900794, 16195255, 17852941)  Currently, vancomycin remains preferred for MRSA bacteremia.  However, linezolid is FDA-approved and potentially front-line therapy for treatment of bacteremia due to vancomycin-resistant enterococcus.(27475738)
• Urinary tract infection:  Although linezolid isn't excreted in the urine, urinary concentrations greatly exceed serum levels.  Linezolid may be used for definite or suspected infection with vancomycin-resistant enterococci.
• Skin and soft-tissue infections.  Linezolid appears to be more effective than vancomycin.(26758498)
• CNS infections?  Linezolid has excellent CSF penetration and some limited evidence suggests that it may be used in meningitis.(23672240, 21671825, 14766894)

toxicity/contraindications

• Serotonin syndrome may occur if combined with other serotonergic medications (although safe in combination with fentanyl).
  • Ideally, serotonergic medications would be stopped and allowed to wash out prior to initiation of linezolid (especially fluoxetine, which has a half-life of several days).(15883150)  However, for critical infections it may be reasonable to simultaneously stop the serotonergic medications and initiate linezolid (with intensive monitoring for serotonin syndrome).(20098528, 23424229, 29950810)  Notably, when linezolid and serotonergic agents are co-administered, the rate of serotonin syndrome is <10%.(23424229)
• Nausea/vomiting and diarrhea are most common side effects.
• Prolonged courses (>10-14 days) are difficult to tolerate due to a variety of toxicities which usually emerge late:
  • Thrombocytopenia, sometimes neutropenia and anemia (reversible)
  • Peripheral neuropathy (reversible) and optic neuropathy (can be irreversible if treatment isn't stopped)
  • Lactic acidosis
• Rarely:  Posterior reversible leukoencephalopathy (PRES), seizures, hypoglycemia.
• Note:  protective against Clostridioides difficile.(22445203, 21504940)

Medscape monograph:  Linezolid

macrolide dosing

• Azithromycin
  • Community-acquired pneumonia or COPD in ICU:  Front-loaded regimen with 500 mg IV daily for three days (long half-life in tissues so will have biologic effect >>3 days).  Alternative regimen:  500 mg IV x1, then 250 mg IV daily x4 days.
  • Legionella pneumonia:  500 mg IV daily for 5-10 days.
  • Morbid obesity or severe illness:  May consider 500 mg IV daily.
• Clarithromycin
  • 500 mg PO twice daily (immediate-release formulation).
  • GFR 10-30 ml/min:  Reduce dose by 50%.
  • GFR < 10 ml/min:  250-500 mg q24hr.
  • No dose adjustment in hepatic dysfunction (kidneys pick up slack in drug excretion).

pharmacology

• Azithromycin:
  • Oral bioavailability of azithromycin is 37% (food decreases absorption).
  • Excretion in the bile, only 6% excreted unchanged in urine.
  • Protein binding:  50%
  • Vd:  30 L/kg
  • Penetration:  Concentrates intracellularly within tissues, with a long half-life (2-4 days).  Penetrates most tissues, but not urine or meninges.
• Clarithromycin:
  • Oral bioavailability is 50%.
  • Excretion:  Mostly excreted in the liver.  25% excreted unchanged in urine.
  • Protein binding:  60%
  • Vd:  3 L/kg
  • Penetration:  Concentrates intracellularly (tissue concentration > serum concentration), poor CSF penetration.
• Mechanism:  blocks the protein from exiting the 50S ribosomal unit (same mechanism as clindamycin).

spectrum 

• Gram-positive coverage:  Some methicillin-sensitive staph aureus, some Group A/B/C/D/G streptococci, some pneumococcus.  Clarithromycin may be superior for gram-positives.
• Haemophilus influenzae and Moraxella catarrhalis (azithromycin > clarithromycin).
• Atypical organisms (e.g. Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila, pertussis, Coxiella burnetii).

use

• Atypical coverage for community-acquired pneumonia.  Evidence suggests mortality benefit in severe community-acquired pneumonia, possibly due to anti-inflammatory effects.
• COPD exacerbation (although doxycycline may be preferable for patients recently on azithromycin).

toxicity/contraindications

• Extremely well tolerated (most common side effect is nausea or diarrhea with oral administration).
• Relatively low rate of Clostridioides difficile, compared to most other antibiotics.
• Contraindicated in myasthenia gravis.
• May cause transaminitis; cholestasis (azithromycin).
• Clarithromycin:
  • May increase QTc and risk of torsade de pointes (not seen clinically with azithromycin).🌊
  • May cause delirium (antibiomania).

Medscape monographs:  Clarithromycin, Azithromycin

metronidazole dosing

• Usual dose:  500 mg IV/PO q8 (no adjustment for renal function).
• 500 mg IV q6hr may be considered in fulminant C. difficile colitis.(9789385999079) 
• Consider 50% dose reduction in Child-Pugh class C cirrhosis.

pharmacology

• Oral bioavailability approaches 100%.
• Excretion:  20% excreted unchanged in urine, mostly excreted in bile.
• Protein binding:  20%
• Vd:  0.7 L/kg
• Penetration:  Lipophilicity and low protein-binding cause metronidazole to distribute widely throughout the total body water (including abscess cavities and CNS).
• Mechanism:  Trojan horse which is converted into bactericidal metabolites by the electron transport chain of anaerobic bacteria.

spectrum

• Best anti-anaerobic agent (better coverage & fewer problems with Clostridioides difficile compared to clindamycin).
• Only covers anaerobes.

use

• Anaerobic coverage (e.g. metronidazole plus cefepime produces broad-spectrum coverage).  Can be used in broad range of infections (e.g. abdominal, CNS, gynecologic, respiratory, bacteremia, or soft tissue).
• Clostridioides difficile (inferior to oral vancomycin; may be used as add-on agent in severe cases or in patients unable to take oral medications).
• Generally avoid adding it to piperacillin-tazobactam or meropenem (these agents have great anaerobic coverage; the only thing that metronidazole adds is Clostridioides difficile coverage).

toxicity/contraindications

• Nausea, diarrhea, dysgeusia
• Can cause encephalopathy, seizure, peripheral neuropathy, or aseptic meningitis (especially with prolonged use).(27504340)
• Rarely:  Stevens-Johnson syndrome, pancreatitis, hemolytic uremic syndrome.

Medscape monograph:  Metronidazole

nafcillin dosing

• Serious infections (e.g., endocarditis):  2 grams IV q4hr.(26373316, 26320109)
• Dose reduce by 50% in decompensated liver failure.  No adjustments for renal dysfunction.
• Monitor liver function tests every week

pharmacology

• Excretion:  Mostly cleared by the liver and biliary tract.  10-30% unchanged drug is excreted in the urine.
• Protein binding:  90%
• Vd:  0.2 L/kg
• Penetration:  Distributes widely, including inflamed meninges (20% serum levels).
• Mechanism:  Inhibits cell wall synthesis by binding to penicillin-binding proteins (primarily 1a, 1b, and 2).

spectrum

• Streptococci groups A, B
• Pneumococci (penicillin-sensitive)
• Methicillin-sensitive staph aureus (MSSA) & methicillin-sensitive staph epidermidis

use

• Main use is for known MSSA infection (including:  endocarditis, hepatic abscess, skin/soft tissue infections, pneumonia).
  • Recent evidence suggests that cefazolin might be superior for many MSSA infections (more on this debate in the cefazolin section above).
  • Nafcillin penetrates the CSF (unlike cefazolin).  Therefore, nafcillin remains front-line therapy for severe MSSA infections with CNS involvement (e.g., MSSA meningitis, MSSA endocarditis with septic emboli).
• Sensitive strains of coagulase-negative staph (Staph epidermidis, Staph haemolyticus, Staph lugdunensis)
• Synergistic en vitro with either vancomycin or daptomycin against staph aureus (clinical relevance to be determined).(22848719)

toxicity/contraindications

• Rash (10% of patients), interstitial nephritis, drug fever
• Thrombocytopenia, leukopenia, hemolytic anemia (may also cause false-positive Coombs test without hemolytic anemia)
• Seizure or myoclonus may occur with high doses
• Phlebitis

Medscape monograph:  Nafcillin

nitrofurantoin dosing

• Nitrofurantoin monohydrate/macrocrystals (Macrobid), 100 mg PO BID.
• Nitrofurantoin macrocrystals (Furadantin suspension, Macrodantin), 50-100 mg q6hr.

pharmacology

• Well absorbed (especially with food), with ~40% excreted unchanged in the urine.
• Protein binding:  60%.
• Volume of distribution:  0.8 L/kg.  Relatively little drugs enters the gastrointestinal tract, so there is minimal effect on fecal flora and low risk of C. difficile.(22546769)
• Penetration:  Active drug is excreted by the kidneys, thereby achieving therapeutic concentrations in the urine.  Alkalotic urine may reduce its efficacy.  Drug levels in the blood are not high enough to be effective against bacteremia.
• Mechanism of action:  Nitrofurantoin is converted by bacterial flavoproteins into highly reactive electrophilic metabolites that have numerous activities, ultimately with bactericidal effect.(30765904)

spectrum: nitrofurantoin covers:

• Gram positives:
  • Most Staph saprophyticus
  • Most Enterococcus faecalis and Enterococcus faecium, including vancomycin resistant enterococci (VRE).(31608743)
  • Some Staphylococcus aureus.
• Gram negatives:
  • Covers most E. coli, most Citrobacter spp., many Klebsiella spp., and some Enterobacter spp (including ESBL and AmpC species).
  • Misses:  Morganella spp., Proteus mirabilis, Providencia spp., Pseudomonas aeruginosa, Serratia marcescens, Stenotrophomonas maltophilia, Acinetobacter spp., carbapenem-resistant enterobacteriaceae (CRE).(22546769, 31608743)
• Drug levels in the urine are generally 50-300 mcg/ml, which is often well above the susceptibility breakpoint of 64 mcg/ml.  Thus, nitrofurantoin may be clinically effective, despite in vitro “intermediate susceptibility.”(22546769)

use

• Uncomplicated cystitis.
• Catheter-associated bacteriuria (in the absence of pyelonephritis, sepsis, or bacteremia).(22546769, 25004793)  Predominantly useful as step-down therapy if the pathogen is known to be sensitive.  

toxicity/contraindications

• ⚠️ Generally considered to be contraindicated if GFR < 30 ml/min.  However, a large retrospective study suggested that cure rates were unaffected by GFR even when below 30 ml/min.(27100576)  Lower GFR does increase the risk of pneumonitis.
• ⚠️ Caution in patients with G6PD deficiency, as nitrofurantoin may increase the risk of hemolytic anemia.
• Prolonged prophylactic use may cause chronic hepatitis or peripheral neuropathy.  Pneumonitis can occur over a shorter time frame, although pneumonitis is more likely among patients taking nitrofurantoin for weeks.
• Rare complications include pancreatitis and lactic acidosis.

Medscape monographs:  Nitrofurantoin

penicillin G dosing

• GFR > 50 ml/min:  2-4 million units (MU) q4
  • Endocarditis with beta-hemolytic streptococci:  24 MU daily, divided in 4-6 doses (e.g., 4 MU IV q4hr).(26373316, 26320109)
  • Endocarditis with enterococcus:  18-30 MU, divided in six doses (e.g., 5 MU IV q4hr).(26373316, 26320109)
  • CNS infection:  4MU q4hr.
• GFR 10-50 ml/min:  1-2 MU q4
• GFR <10 ml/min:  1-2 MU q6

pharmacology

• Excretion:  80% excreted unchanged in the urine.
• Protein binding:  60%
• Vd:  0.3 L/kg
• Penetration:  most fluids and tissues, including inflamed meninges.

spectrum

• Gram positives:
  • Group A, B, C, G streptococci are susceptible
  • Streptococcus pneumoniae:  generally susceptible for non-meningeal infections
• Neisseria meningitidis
• Anaerobes:
  • Clostridia (excluding Clostridioides difficile) are uniformly susceptible
  • Most oral anaerobes

use

• Rarely used for empiric therapy, but it is definitive therapy for susceptible organisms.  Most common examples of this are as follows:
• 1) Group A, B, C, G streptococci (uniformly susceptible)
• 2) Streptococcus pneumoniae known to be PCN-sensitive
  • Infection outside CSF:  Susceptible if MIC 2 mcg/ml or lower.
  • CNS infection:  Susceptible if MIC is 0.06 mcg/ml or lower.
• 3) Neisseria meningitidis
• 4) Clostridia perfringens

toxicity/contraindications

• Hypersensitivity (rash, anaphylaxis, interstitial nephritis, hepatitis, drug fever)
• Neurotoxicity at high doses (myoclonus, seizure, confusion)
• Thrombocytopenia, leukopenia, hemolytic anemia (may also cause false-positive Coombs test without hemolytic anemia)

Medscape monograph:  Penicillin G

piperacillin-tazobactam dosing

• GFR >20 ml/min:  4.5g q8hr (extended infusion over four hours).
• GFR <20 ml/min:  4.5g q12hr (extended infusion over four hours).
• Morbid obesity:  higher doses may be required.(23228881)

pharmacology

• Excretion:  ~70% excreted unchanged in the urine.
• Protein binding:  ~30%.
• Vd:  ~0.3 L/kg.
• Penetration is excellent, including some entry into inflamed meninges.  Extremely high penetration of the bile may make this a good choice for biliary tract infections.
• Mechanism:  inhibits synthesis of bacterial cell wall.

spectrum

• Gram-positive coverage:
  • Covers:  MSSA, non-enterococcal streptococci, vancomycin-sensitive enterococcus, Staph. saprophyticus.
  • Misses:  MRSA, vancomycin-resistant enterococci, coagulase-negative staph.
• Gram-negative coverage:  Excellent coverage of most Enterobacteriaceae and Pseudomonas.
  • ⚠️ Be careful with bacteria that are resistant to ceftriaxone and sensitive to piperacillin-tazobactam (especially E. coli & Klebsiella pneumoniae); this sensitivity pattern suggests extended-spectrum beta-lactamase resistant bacteria, which may be better treated with a carbapenem (see ESBL below).(30208454)
• Anaerobic coverage:  Excellent (misses C. difficile)

use

• Septic shock.
• Intra-abdominal infections, biliary sepsis, urosepsis.
• Nosocomial pneumonia.

toxicity/contraindications

• Rash, drug fever.
• Leukopenia, thrombocytopenia.
• Associated with lower rate of C. difficile than broad-spectrum cephalosporins (e.g., cefepime).
• Prolonged prothrombin time (specifically in renal failure).(31608743)

Medscape monograph: Piperacillin-tazobactam

rifampin dosing

• Meningitis:  600 mg q12.(26320109)
• Prosthetic valve endocarditis:  300 mg q8.(26373316, 26320109) 
  • 🛑 Consider delaying initiation of rifampin until after 3-5 days of effective therapy (this may avoid rifampin resistance).

pharmacology

• Oral bioavailability:  95%
• Excretion: Hepatic metabolism, mostly excreted into bile.  15% excreted unchanged in urine.
• Protein binding:  80%
• Vd:  0.9 L/kg
• Penetration:
  • Good penetration of most tissues including bone, joint, and meninges (~10-20% penetration of meninges; compare to vancomycin's 1-5% penetration).(28870736)
  • Excellent penetration of biofilms, may help sterilize foreign bodies which cannot be removed (e.g. prosthetic valve endocarditis).
• Mechanism:  Inhibits bacterial RNA polymerase

spectrum

• Staph aureus (including MRSA), coagulase-negative staph
• Streptococcus pneumoniae, Group A streptococcus
• Acinetobacter baumannii
• Legionella, listeria
• Mycobacteria including tuberculosis

use

• Note:  Rifampin is generally used as an adjunctive agent to avoid emergence of resistance.
• Prosthetic valve endocarditis
• Prosthetic joint infections
• Meningitis
  • Community-acquired:  targeted especially at treatment of PCN-resistant Streptococcus pneumoniae.
  • Nosocomial:  used in hardware-associated meningitis/ventriculitis.
• Legionella infections
• Tuberculosis

toxicity/contraindications

• Interacts with many medications.
• Discoloration of bodily fluids
• Hepatitis
• Nausea/vomiting, abdominal pain
• Rarely:  Thrombocytopenia, leukopenia, hemolytic anemia

Medscape monograph:  Rifampin

tigecycline dosing

• Loading dose 100 mg, then 50 mg IV Q12hr (for serious infection 100 mg IV Q12 may be better).
• High-dose tigecycline (serious systemic infections):  Loading dose of 200-400 mg IV, then 100-200 mg IV q24.
• No dose adjustment for renal dysfunction.
• In Child-Pugh Class C cirrhosis, reduce maintenance dose by 50%.
• Consider monitoring CBC, INR, lipase, and LFTs q48hr.(29363242)

pharmacology

• Excretion:  Mostly excreted unchanged by the liver into the bile.  10-20% excreted unchanged in urine.
• Protein binding:  89%
• Vd:  ~8 L/kg (16080071)
• Penetration
  • Extensively enters the tissues (e.g. concentrated in alveolar macrophages, gallbladder, and colon).
  • Low levels in blood and urine (not good for bacteremia; maybe OK for urinary tract infection)
• Mechanism:  Inhibition of protein synthesis through 30s ribosomal binding blocking aminoacyl-tRNA (same as doxycycline).

spectrum

• Covers all gram-positive cocci (including MRSA and vancomycin-resistant enterococci).
• Good gram-negative coverage (but misses Pseudomonas, most Proteus and Providencia, and some Morganella).  Can be used against a range of multi-drug resistant gram negatives (e.g. ESBL, AmpC, carbapenemase-producing enterobacteriaceae)
• Covers most anaerobes, including Clostridioides difficile.
• Covers listeria, Mycoplasma pneumoniae, Chlamydia pneumoniae.

use

• Add-on agent for fulminant Clostridioides difficile (suppresses toxin production by Clostridioides while simultaneously working against colonic flora which have translocated out of the bowel).(29363242)
• Extremely drug-resistant bacteria (approved for community-acquired pneumonia, skin/soft tissue infection, and complicated intra-abdominal infection)
• FDA approved for soft tissue infection, complicated intra-abdominal infections, and pneumonia.  However, they are generally not front-line, given concerns about potential of increased mortality (see FDA communication here).  This may reflect low drug levels in the blood.

toxicity/contraindications

• Nausea/vomiting (may avoid with slow infusion)
• Pancreatitis, hepatitis
• Coagulation abnormality, low fibrinogen level
• Anaphylactoid reactions

Medscape monograph:  Tigecycline

dosing (based on trimethoprim component)

• Basics:
  • Single-strength tablet = 80 mg trimethoprim & 400 mg sulfamethoxazole.
  • Double-strength tablet = 160 mg trimethoprim & 400 mg sulfamethoxazole.
• Pneumocystis jirovecii:  daily dose of 15 mg/kg = 5 mg/kg q8 (~two double-strength tablets q8hr).
• Serious bacterial infection in ICU:  daily dose of 10 mg/kg = 2.5 mg/kg q6 (~one double-strength tablet q6hr).
• Urinary tract or skin/soft tissue infection:  daily dose of ~5 mg/kg (~one double-strength tablet q12hr).(21930870)
• Renal dosing:
  • GFR 15-30 ml/min:  use 50-75% of usual dose.
  • GFR <15 ml/min:  avoid unless Pneumocystis jirovecii; use 25-50% of usual dose.
• Co-administration of folinic acid may prevent cytopenias, without affecting antibacterial effects (except possibly against enterococci).

pharmacology

• >90% oral bioavailability.
• Excretion:  ~50% excreted unchanged in urine, achieving a high urinary drug concentration.
• Protein binding:  60%.
• Vd:  1.8 L/kg trimethoprim; 0.3 L/kg sulfamethoxazole.
• Penetration:  Excellent penetration of most tissues, including CSF (40% serum levels).
• Extensively metabolized by liver, cleared by kidneys.

spectrum:  TMP-SMX covers:  

• Gram-positives:
  • Group A and B streptococci.
  • Staphylococcus saprophyticus.
  • MSSA, and >90% of MRSA isolates. (20507860)
  • Streptococcus pneumoniae (~70%).
  • Misses Enterococcus spp.
• Gram-negatives
  • Overall very good (better than ampicillin/sulbactam).
  • Sensitivity of E. coli is falling in many regions.  However, TMP-SMX may be more effective against other enterobacteriaceae (e.g., Enterobacter spp., Serratia spp.).
  • Misses Pseudomonas, but covers Stenotrophomonas maltophilia.
• Anaerobes:  Covers most gram-negative anaerobes, including Bacteroides
• Weird stuff:  Legionella, Pneumocystis jirovecii, nocardia, Listeria monocytogenes, toxoplasmosis.

use

• Pneumocystis jirovecii.
• Listeria, toxoplasmosis, legionella.
• MRSA infections (particularly skin; appears inferior to vancomycin for MRSA bacteremia).(20507860, 25977146)
• Pneumonia (but limited by increasing resistance among streptococcus pneumoniae)
• Urinary tract infections and prostatitis (due to sensitive organisms, not as empiric therapy).

toxicity/contraindications

• Overall generally well tolerated, but in the context of HIV causes lots of hypersensitivity reactions.
• Hypersensitivity (rash, drug fever, aseptic meningitis, rarely Stevens Johnson Syndrome).
• Renal dysfunction (usually this is pseudo-elevation of creatinine, but can also cause interstitial nephritis or crystalluria with genuine renal dysfunction).
• Hyperkalemia (avoid use in combination with ACEi/ARB or spironolactone).
• Hepatitis, cholestasis, liver failure.
• Methemoglobinemia or hemolysis in patients with severe G6PD deficiency.
• Neutropenia, thrombocytopenia, leukopenia with high doses.
• Pregnancy, lactation.

Medscape monograph:  Trimethoprim-Sulfamethoxazole

vancomycin dosing

• Loading dose of 25 mg/kg may be considered (critical illness, endocarditis, pneumonia, CNS infections).
• Maintenance dose is 15 mg/kg, with the conventional dosing interval dependent on renal function:
  • GFR >70:  q12.
  • GFR 30-70:  q24.
  • GFR 20-30:  q48.
  • GFR <20 or continuous renal replacement therapy (CRRT):  serially check levels q24hr, re-dose when sub-therapeutic (roughly q3-7 days).
  • Intermittent hemodialysis (IHD):  Load with 20 mg/kg, then administer 8 mg/kg during the last hour of each hemodialysis session.
• Conventional vancomycin dosing is based on trough levels:
  • Skin/soft tissue infection:  target 10-15 mcg/ml.
  • Bacteremia, endocarditis, pneumonia, meningitis:  target 15-20 mcg/ml.
  • Troughs <10 mcg/ml may promote emergence of resistant bacteria.
• It's probably preferable to dose vancomycin based on individual patient pharmacokinetics.🌊  Institutional approaches to vancomycin dosing vary widely, when in doubt consult with a pharmacist.

pharmacology

• Excretion:  90% excreted unchanged in urine.
• Protein binding:  ~50% protein binding
• Vd:  0.7 L/kg
• Penetration
  • Penetrates body fluids well, but limited penetration of lung or CSF.
  • Intravenous vancomycin has no meaningful activity against Clostridioides difficile (it must be given orally for that application).
• Mechanism:  cell wall synthesis inhibited by binding to D-alanyl-D-alanine precursor and inhibiting peptidoglycan polymerization.

spectrum:  basically all gram-positives except VRE

• MSSA (but less effective than beta-lactams)
• MRSA (although efficacy depends on MIC)
• Enterococci except for vancomycin-resistant enterococci (VRE), which are usually Enterococcus faecium.
  • However, for E. faecalis bacteremia or endocarditis, add ampicillin or gentamicin for synergy.

interpreting vancomycin MIC in the context of MRSA

• MIC 1 ug/ml or below:  Susceptible
• MIC 1.5 ug/mL is intermediate.  Avoid vancomycin if possible.  If vancomycin must be used, an AUC24 of at least 600 should be ensured to achieve efficacy (unfortunately this dose of vancomycin will increase the risk of nephrotoxicity).(26105168)
• MIC 2 or higher ug/mL:  Resistant

reasons vancomycin is often a sub-optimal antibiotic

• Nephrotoxic (rising resistance over time forces us to target higher vancomycin levels, which increases toxicity).
• Requires dose adjustment & monitoring of levels.
• For beta-lactam sensitive organisms, a beta-lactam is more effective (vancomycin provides broad-spectrum yet weaker coverage).
• Suboptimal penetration of lungs and meninges.
• Less effective for MRSA with a minimum inhibitory concentration (MIC) of 1.5 mg/ml or greater, a situation in which a different antibiotic may be more effective.(26320109)
• Penicillin allergy is traditionally a major reason for the use of vancomycin.  However, penicillin has a low rate of cross-allergy with cefazolin and third/fourth generation cephalosporins, so “penicillin allergy” is a poor rationale for vancomycin use.
• Vancomycin should be avoided for empiric treatment of urinary tract infections or intra-abdominal infections.  MRSA isn't a common pathogen at these sites, whereas Enterococcus faecium may be more likely.  If you're really looking for an extended-spectrum gram-positive agent for infections at these sites, linezolid might be more appropriate (however, coverage with a single agent such as piperacillin-tazobactam is usually fine).

use

• Empiric coverage for MRSA in the context of septic shock, endocarditis, vascular catheter infection, skin/soft tissue infection.
• Known MRSA infections.
• Great choice for patients on chronic dialysis (the main drawback of vancomycin is nephrotoxicity).

toxicity/contraindications

• Nephrotoxicity is the primary concern.
• Fever/chills, phlebitis
• Cytopenias:
  • Neutropenia, especially with prolonged use
  • Thrombocytopenia:  may cause acute, severe thrombocytopenia due to immune platelet consumption
• Red person syndrome:  rapid infusion of vancomycin can cause histamine release with erythema and hypotension (anaphylactoid reaction).  This is not an allergy, the drug may still be given at a slower rate.
• Severe dermatologic reactions:  drug rash with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP).

Medscape monograph:  Vancomycin.

The AmpC gene is an inducible beta-lactamase.  Normally this gene is suppressed, so it may be undetectable in laboratory tests.  However, en vivo the enzyme can turn on and render bacteria resistant, leading to treatment failure (despite the laboratory's reporting that the bacteria was “sensitive”).  The beta-lactamase gene can turn on within a timeframe of one day to a couple weeks, so treatment may work initially – yet subsequently fail.

diagnosis

• The AmpC resistance gene tends to occur in the “SPICE“ organisms:
  • Serratia species.
  • Providentia species.
  • Indole-positive proteus (including Proteus vulgaris and Proteus penneri – but not Proteus mirabilis).
  • Citrobacter species.
  • Enterobacter species.
• This may also occur in Morganella morganii, Klebsiella aerogenes, Hafnia alvei, Yersinia species, Pseudomonas species, Acinetobacter species.

treatment

• It's unclear exactly which antibiotics can be used here.  Any antibiotics to which the bacteria are resistant en vitro on susceptibility testing should obviously be avoided.  Third-generation cephalosporins should also be avoided given evidence of clinical failures.
• Front-line therapies:
  • Carbapenems are the gold standard for deep-seated, life-threatening infection (especially if the patient fails to respond adequately to initial therapy).
  • Cefepime is more stable against AmpC beta-lactamases, often used.(28320724)
• Probably adequate:  Piperacillin-tazobactam doesn't induce the production of AmpC beta-lactamases.  It appears to be effective in several studies, although this remains a bit controversial.(28320724, 26542304, 30125680, 28034519)
• Other options:  Non-beta lactam antibiotics aren't susceptible to AmpC beta-lactamase (including aminoglycosides, fluoroquinolones, trimethoprim-sulfamethoxazole, and nitrofurantoin).

ESBL refers to plasmids which confer resistance to most beta-lactams, except for cephamycins (cefoxitin, cefotetan, and cefmetazole) and carbapenems.  They are generally susceptible to beta-lactamase inhibitors (e.g. sulbactam and tazobactam), potentially leaving these bacteria sensitive to combinations such as piperacillin-tazobactam.

diagnosis

• Most common among Klebsiella pneumoniae, Klebsiella oxytoca, or E. coli.  However, can occur in a variety of gram-negative bacilli.
• May be suspected on the basis of an unusual in vitro sensitivity pattern:
  • Sensitive to cephamycins (cefoxitin, cefotetan, cefmetazole)
  • Resistant to 3rd & 4th-generation cephalosporins
  • Often sensitive to beta-lactamase inhibitors (e.g. piperacillin-tazobactam)
• Many microbiology laboratories will recognize these patterns and report out that the species is an ESBL.

treatment

Caution:  Most beta-lactam antibiotics shouldn't be used (regardless of whether they are reported out as “sensitive” by the laboratory).

carbapenems

• Meropenem or imipenem are the gold standard therapy for severe infection.
• Ertepenem:  May be OK for less severe infection.  Some studies have shown trends towards increased mortality with ertapenem.  This may relate to inadequate dosing of ertapenem (the standard 1 gram/day regimen may fail to achieve adequate levels; 1.5-2 grams/day may be superior)(31369411)

beta-lactam/beta-lactam inhibitor combinations

• Observational studies show mixed results (no obvious increase in mortality vs. carbapenems).
• MERINO trial (30208454)
  • RCT of patients with E. coli or K pneumoniae bacteremia resistant to ceftriaxone and “sensitive” to piperacillin-tazobactam.  About 60% had bacteremia due to  a urinary tract source.  ESBL production was confirmed in 86% of cases.  Patients were randomized to receive piperacillin-tazobactam (4.5 grams q6hr) or meropenem (1 gram q8hr).
  • 30-day mortality was 12% (23/187) in piperacillin-tazobactam group vs. 4% (7/191) in the meropenem group (p=0.002 with fragility index of five).
  • Limitations:  Many deaths were ascribed to noninfectious complications of malignancy.
  • Overall this is the highest quality evidence available here, and it shows a potential signal of harm with piperacillin-tazobactam.
• It remains conceivable that piperacillin-tazobactam might be adequate in ESBL E. coli limited to the urinary tract.(22057701, 22057699, 22915465, 16723596)   

other antibiotics: 

• Trimethoprim-Sulfamethoxazole:  May be used as oral step-down agent once patient recovering, if susceptible.
• Fosfomycin and nitrofurantoin:  May be used for uncomplicated cystitis.(31369411)

basics

• Augmented Renal Clearance (ARC) refers to supranormal kidney function (GFR >130).  This may result from hyperdynamic circulation in the context of physiological stress.
• ARC may lead to occult underdosing of antibiotics cleared by the kidney.  The significance of antibiotic underdosing can be difficult to prove, because ARC also correlates with patients who have robust organ function reserves who tend to fare well regardless.(32055559)  
• Some patients may be definitively diagnosed with ARC, based on unusually low drug levels (e.g., aminoglycoside, vancomycin, and perhaps enoxaparin).  Unfortunately, in most patients it may be impossible to clearly make this diagnosis.

risk factors for ARC

• Younger age (e.g., <50 years old), male sex.
• Less profound illness (e.g., absence of multiorgan failure).
• Certain diseases:  trauma, burns, severe neurologic injury (especially traumatic brain injury or subarachnoid hemorrhage), sepsis.(30723936)  
• Absence of chronic renal insufficiency or diabetes.
• Low serum creatinine (<0.7 mg/dL).

management:  if using a renally cleared antibiotic

• Use the maximal approved dosage.(32659898)
• Administer doses in a prolonged infusion, if possible.
• Monitor drug levels, if possible.

management:  switching to an agent less dependent on renal function

Follow us on iTunes

To keep this page small and fast, questions & discussion about this post can be found on another page here.

• Double-coverage for pseudomonas is generally unnecessary and poorly supported by evidence.
• Over-utilization of:
  •  Fluoroquinolones and ceftazidime – almost never needed.
  • Clindamycin – generally should be avoided except in toxic shock or severe group A streptococcal infections.
• Be careful for species with inducible AmpC genes (e.g., Serratia spp., Providencia spp., Proteus vulgaris, Citrobacter spp., Enterobacter spp.).  These may develop resistance to beta-lactams, causing treatment failure even if the antibiotic appears “sensitive” en vitro.
• Be wary for the presence of ESBL species if gram-negatives (especially E. coli or Klebsiella) appear sensitive to piperacillin-tazobactam but resistant to third and fourth-generation cephalosporins.
• For many non-MRSA gram positives, vancomycin is less powerful and has inferior tissue penetration compared to beta-lactams.  Thus, vancomycin isn't optimal therapy for MSSA or streptococcal species.

Guide to emoji hyperlinks 

• 
   = Link to online calculator.
•  = Link to Medscape monograph about a drug.
• 
   = Link to IBCC section about a drug.
•  = Link to IBCC section covering that topic.
•  = Link to FOAMed site with related information.
•  = Link to supplemental media.

• Special Acknowledgement:  Pharmacokinetics and doses listed above were largely drawn from the Hopkins Antibiotic Guide and Antibiotic Essentials 15th Ed. by Cunha & Cunha.  
• 12627936  Chow KM, Szeto CC, Hui AC, Wong TY, Li PK. Retrospective review of neurotoxicity induced by cefepime and ceftazidime. Pharmacotherapy. 2003 Mar;23(3):369-73. doi: 10.1592/phco.23.3.369.32100  [PubMed]
• 14763949  Orhan F, Odemis E, Yaris N, Okten A, Erduran E, Durmaz M, Yayla S. A case of IgE-mediated hypersensitivity to cefepime. Allergy. 2004 Feb;59(2):239-41. doi: 10.1046/j.1398-9995.2003.00376.x  [PubMed]
• 14766894  Krueger WA, Kottler B, Will BE, Heininger A, Guggenberger H, Unertl KE. Treatment of meningitis due to methicillin-resistant Staphylococcus epidermidis with linezolid. J Clin Microbiol. 2004 Feb;42(2):929-32. doi: 10.1128/JCM.42.2.929-932.2004  [PubMed]
• 14963072  Alston WK, Ahern JW. Increase in the rate of nosocomial Clostridium difficile-associated diarrhoea during shortages of piperacillin-tazobactam and piperacillin. J Antimicrob Chemother. 2004 Mar;53(3):549-50. doi: 10.1093/jac/dkh127  [PubMed]
• 15883150  Morales N, Vermette H. Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine. Psychosomatics. 2005 May-Jun;46(3):274-5. doi: 10.1176/appi.psy.46.3.274  [PubMed]
• 16080071  Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S333-40. doi: 10.1086/431674  [PubMed]
• 16195255  Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother. 2005 Nov;56(5):923-9. doi: 10.1093/jac/dki355  [PubMed]
• 16723596  Gavin PJ, Suseno MT, Thomson RB Jr, Gaydos JM, Pierson CL, Halstead DC, Aslanzadeh J, Brecher S, Rotstein C, Brossette SE, Peterson LR. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother. 2006 Jun;50(6):2244-7. doi: 10.1128/AAC.00381-05  [PubMed]
• 17158033  Roberts JA, Webb SA, Lipman J. Cefepime versus ceftazidime: considerations for empirical use in critically ill patients. Int J Antimicrob Agents. 2007 Feb;29(2):117-28. doi: 10.1016/j.ijantimicag.2006.08.031  [PubMed]
• 17548489  Pai MP, Norenberg JP, Anderson T, Goade DW, Rodvold KA, Telepak RA, Mercier RC. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother. 2007 Aug;51(8):2741-7. doi: 10.1128/AAC.00059-07  [PubMed]
• 17852941  Mancino P, Ucciferri C, Falasca K, Pizzigallo E, Vecchiet J. Methicillin-resistant Staphylococcus epidermidis (MRSE) endocarditis treated with linezolid. Scand J Infect Dis. 2008;40(1):67-73. doi: 10.1080/00365540701509915  [PubMed]
• 17899228  Lentino JR, Narita M, Yu VL. New antimicrobial agents as therapy for resistant gram-positive cocci. Eur J Clin Microbiol Infect Dis. 2008 Jan;27(1):3-15. doi: 10.1007/s10096-007-0389-y  [PubMed]
• 18171186  Baxter R, Ray GT, Fireman BH. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol. 2008 Jan;29(1):44-50. doi: 10.1086/524320  [PubMed]
• 18719064  Wunderink RG, Mendelson MH, Somero MS, Fabian TC, May AK, Bhattacharyya H, Leeper KV Jr, Solomkin JS. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest. 2008 Dec;134(6):1200-1207. doi: 10.1378/chest.08-0011  [PubMed]
• 19072714  Wilcox MH, Tack KJ, Bouza E, Herr DL, Ruf BR, Ijzerman MM, Croos-Dabrera RV, Kunkel MJ, Knirsch C. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis. 2009 Jan 15;48(2):203-12. doi: 10.1086/595686  [PubMed]
• 19900794  Beibei L, Yun C, Mengli C, Nan B, Xuhong Y, Rui W. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2010 Jan;35(1):3-12. doi: 10.1016/j.ijantimicag.2009.09.013  [PubMed]
• 20098528  Quinn DK, Stern TA. Linezolid and serotonin syndrome. Prim Care Companion J Clin Psychiatry. 2009;11(6):353-6. doi: 10.4088/PCC.09r00853  [PubMed]
• 20507860  Goldberg E, Paul M, Talker O, Samra Z, Raskin M, Hazzan R, Leibovici L, Bishara J. Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: a retrospective cohort study. J Antimicrob Chemother. 2010 Aug;65(8):1779-83. doi: 10.1093/jac/dkq179  [PubMed]
• 21163725  Pletz MW, Burkhardt O, Welte T. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? – Comparison of pharmacology and clinical efficacy. Eur J Med Res. 2010 Nov 30;15(12):507-13. doi: 10.1186/2047-783x-15-12-507  [PubMed]
• 21504940  Baines SD, Noel AR, Huscroft GS, Todhunter SL, O'Connor R, Hobbs JK, Freeman J, Lovering AM, Wilcox MH. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model. J Antimicrob Chemother. 2011 Jul;66(7):1537-46. doi: 10.1093/jac/dkr155  [PubMed]
• 21671825  Sipahi OR, Bardak S, Turhan T, Arda B, Pullukcu H, Ruksen M, Aydemir S, Dalbasti T, Yurtseven T, Zileli M, Ulusoy S. Linezolid in the treatment of methicillin-resistant staphylococcal post-neurosurgical meningitis: a series of 17 cases. Scand J Infect Dis. 2011 Oct;43(10):757-64. doi: 10.3109/00365548.2011.585177  [PubMed]
• 21930870  Cadena J, Nair S, Henao-Martinez AF, Jorgensen JH, Patterson JE, Sreeramoju PV. Dose of trimethoprim-sulfamethoxazole to treat skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2011 Dec;55(12):5430-2. doi: 10.1128/AAC.00706-11  [PubMed]
• 22057699  Perez F, Bonomo RA. Can we really use ß-lactam/ß-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ß-lactamase-producing bacteria? Clin Infect Dis. 2012 Jan 15;54(2):175-7. doi: 10.1093/cid/cir793  [PubMed]
• 22057701  Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual Á; Extended-Spectrum Beta-Lactamases–Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012 Jan 15;54(2):167-74. doi: 10.1093/cid/cir790  [PubMed]
• 22247123  Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012 Mar 1;54(5):621-9. doi: 10.1093/cid/cir895  [PubMed]
• 22249886  Rich BS, Keel R, Ho VP, Turbendian H, Afaneh CI, Dakin GF, Pomp A, Nicolau DP, Barie PS. Cefepime dosing in the morbidly obese patient population. Obes Surg. 2012 Mar;22(3):465-71. doi: 10.1007/s11695-011-0586-8  [PubMed]
• 22445203  Valerio M, Pedromingo M, Muñoz P, Alcalá L, Marin M, Peláez T, Giannella M, Bouza E. Potential protective role of linezolid against Clostridium difficile infection. Int J Antimicrob Agents. 2012 May;39(5):414-9. doi: 10.1016/j.ijantimicag.2012.01.005  [PubMed]
• 22546769  Cunha BA, Schoch P, Hage JE. Oral therapy of catheter-associated bacteriuria (CAB) in the era of antibiotic resistance: nitrofurantoin revisited. J Chemother. 2012 Apr;24(2):122-4. doi: 10.1179/1120009X12Z.00000000013  [PubMed]
• 22563022  Doernberg SB, Winston LG, Deck DH, Chambers HF. Does doxycycline protect against development of Clostridium difficile infection? Clin Infect Dis. 2012 Sep;55(5):615-20. doi: 10.1093/cid/cis457  [PubMed]
• 22787406*  Ager S, Gould K. Clinical update on linezolid in the treatment of Gram-positive bacterial infections. Infect Drug Resist. 2012;5:87-102. doi: 10.2147/IDR.S25890  [PubMed]
• 22848719  Leonard SN. Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. PLoS One. 2012;7(7):e42103. doi: 10.1371/journal.pone.0042103  [PubMed]
• 22915465  Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012 Dec;67(12):2793-803. doi: 10.1093/jac/dks301  [PubMed]
• 23147743  Hites M, Taccone FS, Wolff F, Cotton F, Beumier M, De Backer D, Roisin S, Lorent S, Surin R, Seyler L, Vincent JL, Jacobs F. Case-control study of drug monitoring of β-lactams in obese critically ill patients. Antimicrob Agents Chemother. 2013 Feb;57(2):708-15. doi: 10.1128/AAC.01083-12  [PubMed]
• 23228881  Cheatham SC, Fleming MR, Healy DP, Chung CE, Shea KM, Humphrey ML, Kays MB. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. Int J Antimicrob Agents. 2013 Jan;41(1):52-6. doi: 10.1016/j.ijantimicag.2012.09.004  [PubMed]
• 23424229  Woytowish MR, Maynor LM. Clinical relevance of linezolid-associated serotonin toxicity. Ann Pharmacother. 2013 Mar;47(3):388-97. doi: 10.1345/aph.1R386  [PubMed]
• 23568605  Jiang H, Tang RN, Wang J. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials. Eur J Clin Microbiol Infect Dis. 2013 Sep;32(9):1121-8. doi: 10.1007/s10096-013-1867-z  [PubMed]
• 23672240  Sipahi OR, Bardak-Ozcem S, Turhan T, Arda B, Ruksen M, Pullukcu H, Aydemir S, Dalbasti T, Yurtseven T, Sipahi H, Zileli M, Ulusoy S. Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus meningitis. Surg Infect (Larchmt). 2013 Aug;14(4):357-62. doi: 10.1089/sur.2012.091  [PubMed]
• 24140078  Muldoon EG, Epstein L, Logvinenko T, Murray S, Doron SI, Snydman DR. The impact of cefepime as first line therapy for neutropenic fever on Clostridium difficile rates among hematology and oncology patients. Anaerobe. 2013 Dec;24:79-81. doi: 10.1016/j.anaerobe.2013.10.001  [PubMed]
• 24238896  Chavanet P. The ZEPHyR study: a randomized comparison of linezolid and vancomycin for MRSA pneumonia. Med Mal Infect. 2013 Dec;43(11-12):451-5. doi: 10.1016/j.medmal.2013.09.011  [PubMed]
• 24420846  Caffrey AR, Morrill HJ, Puzniak LA, Laplante KL. Comparative effectiveness of linezolid and vancomycin among a national veterans affairs cohort with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy. 2014 May;34(5):473-80. doi: 10.1002/phar.1390  [PubMed]
• 24637693  Blumenthal KG, Youngster I, Shenoy ES, Banerji A, Nelson SB. Tolerability of cefazolin after immune-mediated hypersensitivity reactions to nafcillin in the outpatient setting. Antimicrob Agents Chemother. 2014 Jun;58(6):3137-43. doi: 10.1128/AAC.02504-13  [PubMed]
• 24916853  Peyrani P, Wiemken TL, Kelley R, Zervos MJ, Kett DH, File TM Jr, Stein GE, Ford KD, Scerpella EG, Welch V, Ramirez JA; IMPACT-HAP Study Group. Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study. Crit Care. 2014 Jun 10;18(3):R118. doi: 10.1186/cc13914  [PubMed]
• 25004793  Cunha BA, Lee P, Kaouris N, Raza M. The safety of nitrofurantoin for the treatment of nosocomial catheter-associated bacteriuria (CAB) and cystitis. J Chemother. 2015 Feb;27(2):122-3. doi: 10.1179/1973947814Y.0000000202  [PubMed]
• 25066668  Niederman MS, Chastre J, Solem CT, Wan Y, Gao X, Myers DE, Haider S, Li JZ, Stephens JM. Health economic evaluation of patients treated for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus: secondary analysis of a multicenter randomized clinical trial of vancomycin and linezolid. Clin Ther. 2014 Sep 1;36(9):1233-1243.e1. doi: 10.1016/j.clinthera.2014.06.029  [PubMed]
• 25124380  Terico AT, Gallagher JC. Beta-lactam hypersensitivity and cross-reactivity. J Pharm Pract. 2014 Dec;27(6):530-44. doi: 10.1177/0897190014546109  [PubMed]
• 25355172  Wang Y, Zou Y, Xie J, Wang T, Zheng X, He H, Dong W, Xing J, Dong Y. Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis. Eur J Clin Pharmacol. 2015 Jan;71(1):107-15. doi: 10.1007/s00228-014-1775-x  [PubMed]
• 25495779  Chuang YC, Wang JT, Lin HY, Chang SC. Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis. BMC Infect Dis. 2014 Dec 13;14:687. doi: 10.1186/s12879-014-0687-9  [PubMed]
• 25977146  Paul M, Bishara J, Yahav D, Goldberg E, Neuberger A, Ghanem-Zoubi N, Dickstein Y, Nseir W, Dan M, Leibovici L. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by methicillin resistant Staphylococcus aureus: randomised controlled trial. BMJ. 2015 May 14;350:h2219. doi: 10.1136/bmj.h2219  [PubMed]
• 26105168  Labreche MJ, Graber CJ, Nguyen HM. Recent Updates on the Role of Pharmacokinetics-pharmacodynamics in Antimicrobial Susceptibility Testing as Applied to Clinical Practice. Clin Infect Dis. 2015 Nov 1;61(9):1446-52. doi: 10.1093/cid/civ498  [PubMed]
• 26320109  Habib G, Lancellotti P, Antunes MJ, et al. ESC Scientific Document Group. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015 Nov 21;36(44):3075-3128. doi: 10.1093/eurheartj/ehv319  [PubMed]
• 26373316  Baddour LM, Wilson WR, Bayer AS, et al.; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2015 Oct 13;132(15):1435-86. doi: 10.1161/CIR.0000000000000296  [PubMed]
• 26382940  Reveles KR, Mortensen EM, Attridge RT, Frei CR. Comparative-effectiveness of vancomycin and linezolid as part of guideline-recommended empiric therapy for healthcare-associated pneumonia. BMC Res Notes. 2015 Sep 17;8:450. doi: 10.1186/s13104-015-1396-1  [PubMed]
• 26542304  Harris PN, Wei JY, Shen AW, Abdile AA, Paynter S, Huxley RR, Pandeya N, Doi Y, Huh K, O'Neal CS, Talbot TR, Paterson DL. Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis. J Antimicrob Chemother. 2016 Feb;71(2):296-306. doi: 10.1093/jac/dkv346  [PubMed]
• 26758498  Yue J, Dong BR, Yang M, Chen X, Wu T, Liu GJ. Linezolid versus vancomycin for skin and soft tissue infections. Cochrane Database Syst Rev. 2016 Jan 7;(1):CD008056. doi: 10.1002/14651858.CD008056.pub3  [PubMed]
• 27025622  Hung YP, Lee JC, Lin HJ, Liu HC, Wu YH, Tsai PJ, Ko WC. Doxycycline and Tigecycline: Two Friendly Drugs with a Low Association with Clostridium Difficile Infection. Antibiotics (Basel). 2015 Jun 19;4(2):216-29. doi: 10.3390/antibiotics4020216  [PubMed]
• 27100576  Santos JM, Batech M, Pelter MA, Deamer RL. Evaluation of the Risk of Nitrofurantoin Lung Injury and Its Efficacy in Diminished Kidney Function in Older Adults in a Large Integrated Healthcare System: A Matched Cohort Study. J Am Geriatr Soc. 2016 Apr;64(4):798-805. doi: 10.1111/jgs.14072  [PubMed]
• 27208687  Tong MC, Wisniewski CS, Wolf B, Bosso JA. Comparison of Linezolid and Vancomycin for Methicillin-Resistant Staphylococcus aureus Pneumonia: Institutional Implications. Pharmacotherapy. 2016 Jul;36(7):731-9. doi: 10.1002/phar.1771  [PubMed]
• 27475738  Chuang YC, Lin HY, Chen PY, Lin CY, Wang JT, Chang SC. Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose. Clin Microbiol Infect. 2016 Oct;22(10):890.e1-890.e7. doi: 10.1016/j.cmi.2016.07.018  [PubMed]
• 27504340  Roy U, Panwar A, Pandit A, Das SK, Joshi B. Clinical and Neuroradiological Spectrum of Metronidazole Induced Encephalopathy: Our Experience and the Review of Literature. J Clin Diagn Res. 2016 Jun;10(6):OE01-9. doi: 10.7860/JCDR/2016/19032.8054  [PubMed]
• 27520326  Burnett YJ, Echevarria K, Traugott KA. Ceftaroline as Salvage Monotherapy for Persistent MRSA Bacteremia. Ann Pharmacother. 2016 Dec;50(12):1051-1059. doi: 10.1177/1060028016664361  [PubMed]
• 28034519  Moy S, Sharma R. Treatment Outcomes in Infections Caused by “SPICE” (Serratia, Pseudomonas, Indole-positive Proteus, Citrobacter, and Enterobacter) Organisms: Carbapenem versus Noncarbapenem Regimens. Clin Ther. 2017 Jan;39(1):170-176. doi: 10.1016/j.clinthera.2016.11.025  [PubMed]
• 28320724  Cheng L, Nelson BC, Mehta M, Seval N, Park S, Giddins MJ, Shi Q, Whittier S, Gomez-Simmonds A, Uhlemann AC. Piperacillin-Tazobactam versus Other Antibacterial Agents for Treatment of Bloodstream Infections Due to AmpC β-Lactamase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2017 May 24;61(6):e00276-17. doi: 10.1128/AAC.00276-17  [PubMed]
• 28702467*  Cosimi RA, Beik N, Kubiak DW, Johnson JA. Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review. Open Forum Infect Dis. 2017 May 2;4(2):ofx084. doi: 10.1093/ofid/ofx084  [PubMed]
• 28819873  Cunha BA, Baron J, Cunha CB. Similarities and differences between doxycycline and minocycline: clinical and antimicrobial stewardship considerations. Eur J Clin Microbiol Infect Dis. 2018 Jan;37(1):15-20. doi: 10.1007/s10096-017-3081-x  [PubMed]
• 28870736  Lee CY, Huang CH, Lu PL, Ko WC, Chen YH, Hsueh PR. Role of rifampin for the treatment of bacterial infections other than mycobacteriosis. J Infect. 2017 Nov;75(5):395-408. doi: 10.1016/j.jinf.2017.08.013  [PubMed]
• 28942574  Lother SA, Press N. Once-Daily Treatments for Methicillin-Susceptible Staphylococcus aureus Bacteremia: Are They Good Enough? Curr Infect Dis Rep. 2017 Sep 23;19(11):43. doi: 10.1007/s11908-017-0599-0  [PubMed]
• 28961942  Avdic E, Wang R, Li DX, Tamma PD, Shulder SE, Carroll KC, Cosgrove SE. Sustained impact of a rapid microarray-based assay with antimicrobial stewardship interventions on optimizing therapy in patients with Gram-positive bacteraemia. J Antimicrob Chemother. 2017 Nov 1;72(11):3191-3198. doi: 10.1093/jac/dkx267  [PubMed]
• 29293890  Wald-Dickler N, Holtom P, Spellberg B. Busting the Myth of “Static vs Cidal”: A Systemic Literature Review. Clin Infect Dis. 2018 Apr 17;66(9):1470-1474. doi: 10.1093/cid/cix1127  [PubMed]
• 29363242  Bishop EJ, Tiruvoipati R, Metcalfe J, Marshall C, Botha J, Kelley PG. The outcome of patients with severe and severe-complicated Clostridium difficile infection treated with tigecycline combination therapy: a retrospective observational study. Intern Med J. 2018 Jun;48(6):651-660. doi: 10.1111/imj.13742  [PubMed]
• 29950810*  Hashemian SMR, Farhadi T, Ganjparvar M. Linezolid: a review of its properties, function, and use in critical care. Drug Des Devel Ther. 2018 Jun 18;12:1759-1767. doi: 10.2147/DDDT.S164515  [PubMed]
• 30125680  McKamey L, Venugopalan V, Cherabuddi K, Borgert S, Voils S, Shah K, Klinker KP. Assessing antimicrobial stewardship initiatives: Clinical evaluation of cefepime or piperacillin/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms. Int J Antimicrob Agents. 2018 Nov;52(5):719-723. doi: 10.1016/j.ijantimicag.2018.08.007  [PubMed]
• 30208454  Harris PNA, Tambyah PA, Lye DC, et al.; MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN). Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. JAMA. 2018 Sep 11;320(10):984-994. doi: 10.1001/jama.2018.12163  [PubMed]
• 30476572  Lee BJ, Wang SK, Constantino-Corpuz JK, Apolinario K, Nadler B, McDanel JS, Scheetz MH, Rhodes NJ. Cefazolin vs. anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections in acutely ill adult patients: Results of a systematic review and meta-analysis. Int J Antimicrob Agents. 2019 Mar;53(3):225-233. doi: 10.1016/j.ijantimicag.2018.11.013  [PubMed]
• 30723936  Cook AM, Hatton-Kolpek J. Augmented Renal Clearance. Pharmacotherapy. 2019 Mar;39(3):346-354. doi: 10.1002/phar.2231  [PubMed]
• 30765904  Gardiner BJ, Stewardson AJ, Abbott IJ, Peleg AY. Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems. Aust Prescr. 2019 Feb;42(1):14-19. doi: 10.18773/austprescr.2019.002  [PubMed]
• 31369411  Gudiol C, Cuervo G, Carratalà J. Optimizing therapy of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae. Curr Opin Crit Care. 2019 Oct;25(5):438-448. doi: 10.1097/MCC.0000000000000646  [PubMed]
• 31608743  Bader MS, Loeb M, Leto D, Brooks AA. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Postgrad Med. 2020 Apr;132(3):234-250. doi: 10.1080/00325481.2019.1680052  [PubMed]
• 32055559  Atkinson AJ Jr. Augmented renal clearance. Transl Clin Pharmacol. 2018 Sep;26(3):111-114. doi: 10.12793/tcp.2018.26.3.111  [PubMed]
• 32659898  Chen IH, Nicolau DP. Augmented Renal Clearance and How to Augment Antibiotic Dosing. Antibiotics (Basel). 2020 Jul 9;9(7):393. doi: 10.3390/antibiotics9070393  [PubMed]